Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

SUMMARY Cytochromes P450 (CYP) 2C8 and 2C9 are polymorphic enzymes responsible for the biosynthesis of vasoactive substances from arachidonic acid including endothelium-derived hyperpolarizing factor. Inter-individual differences in the action of these substances might be important in the pathogenesis of cardiovascular diseases such as acute myocardial infarction (AMI) and hypertension. This study describes the relationship between genetic variants of CYP2C8 and CYP2C9, and morbidity in myocardial infarction in a large Swedish patient material. The study included 1172 AMI patients and 1503 control subjects (matched by age, sex and residential area) who participated in the Stockholm Heart Epidemiology Program (SHEEP). Genotyping was performed by allelic discrimination using a 5'-nuclease assay for the CYP2C8 and CYP2C9 variants. To estimate associations to AMI risks, odds ratios (OR) with 95% confidence intervals (CI) were calculated. The frequencies of CYP2C8*1, 2C8*3, 2C9*1, 2C9*2 and 2C9*3 variants in the control group were 0.91, 0.095, 0.83, 0.11 and 0.065, respectively. The risk of AMI in the female individuals carrying the *2 or *3 variant alleles of CYP2C9 and that of all individuals carrying the *3 variant of CYP2C8 was higher [OR (95% CI): 1.3 (1.0-1.9), P = 0.09; 1.5 (1.0-2.2), P = 0.06 and 1.2 (1.0-1.5), P = 0.07, respectively] compared to the groups with CYP2C8*1 and CYP2C9*1. Possession of rare genetic variants of the CYP2C8 and CYP2C9 genes in females is associated with a modest increase in risk of AMI. This might be related to genetic differences in the formation of endogenous vasoregulating eicosanoids.

[1]  H. Izawa,et al.  Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. , 2002, The New England journal of medicine.

[2]  U. de Faire,et al.  Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. , 2002, Biochemical and biophysical research communications.

[3]  K. Okumura,et al.  The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. , 2002, International journal of cardiology.

[4]  H. Roh,et al.  Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations , 2002, European Journal of Clinical Pharmacology.

[5]  U. Yasar,et al.  Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. , 2002, British journal of clinical pharmacology.

[6]  U. Yasar,et al.  Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. , 2002, British journal of clinical pharmacology.

[7]  Erik Eliasson,et al.  Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype , 2002, Clinical pharmacology and therapeutics.

[8]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[9]  I. Fleming,et al.  Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology , 2022 .

[10]  E. Spina,et al.  Severe phenytoin intoxication in a subject homozygous for CYP2C9*3 , 2001, Clinical pharmacology and therapeutics.

[11]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[12]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.

[13]  R. Tyndale,et al.  Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. , 2001, Canadian journal of physiology and pharmacology.

[14]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[15]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[16]  M. Ingelman-Sundberg,et al.  Role of CYP2C9 polymorphism in losartan oxidation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  R. Busse,et al.  Phosphorylation of Thr495 Regulates Ca2+/Calmodulin-Dependent Endothelial Nitric Oxide Synthase Activity , 2001 .

[18]  T. Lu,et al.  EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. , 2001, American journal of physiology. Heart and circulatory physiology.

[19]  A. Ahlbom,et al.  Family History of Coronary Heart Disease, a Strong Risk Factor for Myocardial Infarction Interacting with Other Cardiovascular Risk Factors: Results from the Stockholm Heart Epidemiology Program (SHEEP) , 2001, Epidemiology.

[20]  R. Busse,et al.  Endothelium-Derived Hyperpolarizing Factor Synthase (Cytochrome P450 2C9) Is a Functionally Significant Source of Reactive Oxygen Species in Coronary Arteries , 2001, Circulation research.

[21]  R. Busse,et al.  Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. , 2000, Hypertension.

[22]  J. Mcgiff,et al.  Is EDHF an epoxyeicosatrienoic acid? , 2000, Trends in pharmacological sciences.

[23]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[24]  E. Nanba,et al.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. , 2000, Pharmacogenetics.

[25]  F. Gonzalez,et al.  Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  A. Righetti,et al.  Role of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries , 2000, Postgraduate medical journal.

[27]  R. Busse,et al.  Cytochrome P450 2C is an EDHF synthase in coronary arteries , 1999, Nature.

[28]  C. Hogstedt,et al.  Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the S heep study , 1999 .

[29]  H. Miura,et al.  Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. , 1999, Circulation.

[30]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[31]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[32]  M. Ingelman-Sundberg,et al.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.

[33]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .

[34]  H. Miura,et al.  Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels. , 1998, Circulation research.

[35]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[36]  J. Falck,et al.  Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. , 1991, The American journal of physiology.